1. Home
  2. VKTX

as 11-12-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Founded: 2012 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 7.2B IPO Year: 2015
Target Price: $109.80 AVG Volume (30 days): 6.1M
Analyst Decision: Strong Buy Number of Analysts: 10
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.93 EPS Growth: N/A
52 Week Low/High: $10.34 - $99.41 Next Earning Date: 10-23-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

VKTX Daily Stock ML Predictions

Stock Insider Trading Activity of Viking Therapeutics Inc. (VKTX)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
MACARTNEY LAWSON VKTX Director Nov 8 '24 Sell $68.67 2,000 $137,333.40 47,965
SINGLETON J MATTHEW VKTX Director Oct 25 '24 Sell $79.50 16,000 $1,272,000.00 9,500
Rouan Sarah Kathryn VKTX Director Oct 25 '24 Sell $80.89 11,000 $889,790.00 0
Lian Brian VKTX President & CEO Sep 20 '24 Sell $71.19 216,130 $15,308,552.90 2,304,927
SINGLETON J MATTHEW VKTX Director Sep 20 '24 Sell $69.50 10,300 $715,850.00 9,500
SINGLETON J MATTHEW VKTX Director Aug 21 '24 Sell $69.72 5,700 $397,430.22 9,500
Lian Brian VKTX President & CEO Aug 19 '24 Sell $66.27 112,870 $7,426,507.68 2,304,927
SINGLETON J MATTHEW VKTX Director Aug 19 '24 Sell $62.52 16,000 $995,453.24 9,500

Share on Social Networks: